Other publication
Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial (Nature Medicine, (2023), 29, 6, (1437-1447), 10.1038/s41591-023-02326-3)
Authors: Mummery C.J., Börjesson-Hanson A., Blackburn D.J., Vijverberg E.G.B., De Deyn P.P., Ducharme S., Jonsson M., Schneider A., Rinne J.O., Ludolph A.C., Bodenschatz R., Kordasiewicz H., Swayze E.E., Fitzsimmons B., Mignon L., Moore K.M., Yun C., Baumann T., Li D., Norris D.A., Crean R., Graham D.L., Huang E., Ratti E., Bennett C.F., Junge C., Lane R.M.
Publisher: Nature Research
Publication year: 2024
Journal: Nature Medicine
Journal name in source: Nature Medicine
Article number: 304
Volume: 30
ISSN: 1078-8956
eISSN: 1546-170X
DOI: https://doi.org/10.1038/s41591-023-02639-3
Publication's open availability at the time of reporting: Open Access
Publication channel's open availability : Partially Open Access publication channel
Web address : https://www.nature.com/articles/s41591-023-02639-3
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/181983815
Downloadable publication This is an electronic reprint of the original article. |  |
